IBImmunityBio IBRX · NASDAQ
$8.31 -3.82% (-$0.33)
- Market cap
- $8.92B
- Enterprise value
- $9.66B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 53.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -45.0%
- Bruto marža
- 94.6%
- Neto marža
- -598.6%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.13
- Free float
- 10.9%
O podjetju
ImmunityBio, Inc. (IBRX) is a biotechnology company specializing in the development of immunotherapeutic treatment therapies for various types of cancer and infectious diseases. The company is engaged in developing innovative approaches that activate patients' immune systems and help them fight diseases. ImmunityBio develops drugs that can stimulate immune response, enhance treatment efficacy, and increase the chances of successful outcomes. With the growing research in the field of immunotherapy and the need for new treatment approaches, ImmunityBio, Inc. has the potential for sustained growth. ImmunityBio, Inc. (IBRX) shares might be an interesting choice for investors seeking involvement in the biotechnology and immunotherapeutic treatment therapies industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Gerald Adcock
Employees
688
Headquarters
San Diego
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke